[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-365270-105":59,"doc-detail-365270-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","development-and-validation-of-a-16-gene-t-cell-related-prognostic-model-in-non-small-cell-lung-cancer","Development and validation of a 16-gene T-cell-related prognostic model in non-small cell lung cancer","","Non-small cell lung cancer (NSCLC) shows heterogeneous T-cell responses that affect prognosis and treatment outcomes. This study analyzed 1,027 NSCLC and 108 non-cancer samples from TCGA using ssGSEA, WGCNA, and differential expression to define T-cell-related subtypes. A prognostic model was built with LASSO Cox regression and externally validated in GEO datasets, integrating immune infiltration, drug sensitivity, and qRT-PCR verification in NSCLC tissues. Results supported robust risk stratification and improved survival prediction with a nomogram.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/development-and-validation-of-a-16-gene-t-cell-related-prognostic-model-in-non-small-cell-lung-cancer/365270/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/development-and-validation-of-a-16-gene-t-cell-related-prognostic-model-in-non-small-cell-lung-cancer/365270.png","ImageObject",300,407,{"name":92,"@type":93},"Mia  ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How was the 16-gene T-cell-related prognostic model developed and validated?","Question",{"text":112,"@type":113},"The model was constructed from TCGA NSCLC and non-cancer samples using ssGSEA, WGCNA, and differential expression, then fit with LASSO Cox regression. It was externally validated using GEO datasets (GSE50081, GSE31210, GSE30219).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What does the model do for patient risk stratification and survival prediction?",{"text":117,"@type":113},"It classifies patients into high- and low-risk groups with significant survival differences and shows predictive performance measured by AUCs for 1-, 3-, and 5-year survival. A nomogram combining risk scores and clinical factors further improves survival prediction.",{"name":119,"@type":110,"acceptedAnswer":120},"How is the model linked to treatment response and immune biology?",{"text":121,"@type":113},"Immune cell infiltration and drug sensitivity were assessed, and differential responses were observed between risk groups for MCL1 and IGF1R inhibitors. qRT-PCR validation confirmed that model genes show differential expression in NSCLC tissues consistent with TCGA data.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},365270,1790185248,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687207024478,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","TYPE Original Research PUBLISHED 07 April 2025  \nDOI 10.3389/fimmu.2025.1566597  \nOPEN ACCESS  \nEDITED BY  \nJing Wang,  \nMass General Brigham, United States  \nREVIEWED BY  \nAdiba Sultana,  \nGuangdong Provincial People’s Hospital, China  \nAnie Day Asa Alindogan,  \nMassachusetts General Hospital, United States  \n*CORRESPONDENCE  \nJianping Liang  \n [ljpzhongshan@163.com](ljpzhongshan@163.com)[ ](ljpzhongshan@163.com)Xiuqiong Xia  \n [zhongshanxxq@126.com](zhongshanxxq@126.com)  \n†These authors have contributed equally to this work  \nRECEIVED 25 January 2025  \nACCEPTED 17 March 2025  \nPUBLISHED 07 April 2025  \nCITATION  \nZhang A, Ting H, Ma J, Xia X, Lao X, Li S and Liang J (2025) Development and validation of a 16-gene T-cell-related prognostic model in non-small cell lung cancer.  \nFront. Immunol. 16:1566597 .  \ndoi: 10.3389/fimmu.2025.1566597  \nCOPYRIGHT  \n© 2025 Zhang, Ting, Ma, Xia, Lao, Li and Liang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nDevelopment and validation of a 16-gene T-cell-related prognostic model in non-small cell lung cancer  \nAnbing Zhang 1,2†, Huang Ting 1,2†, Jun Ma 1,2, Xiuqiong Xia 1*, Xiaoli Lao 1,3, Siqi Li 1 and Jianping Liang 1,3*  \n1 Department of Pulmonary and Critical Care Medicine, Zhongshan People’s Hospital, Zhongshan, China, 2Shenzhen University Medical School, Shenzhen University, Shenzhen, China, 3Graduate School, Guangdong Medical University, Zhanjiang, China  \nBackground: Non-small cell lung cancer (NSCLC) exhibits variable T-cell responses, inﬂuencing prognosis and outcomes.  \nMethods: We analyzed 1,027 NSCLC and 108 non-cancerous samples from TCGA using ssGSEA, WGCNA, and differential expression analysis to identify T-cell-related subtypes. A prognostic model was constructed using LASSO Cox regression and externally validated with GEO datasets (GSE50081, GSE31210, GSE30219) . Immune cell inﬁltration and drug sensitivity were assessed. Gene expression alterations were validated in NSCLC tissues using qRT-PCR.  \nResults: A 16-gene prognostic model (LATS2, LDHA, CKAP4, COBL, DSG2, MAPK4, AKAP12, HLF, CD69, BAIAP2L2, FSTL3, CXCL13, PTX3, SMO, KREMEN2, HOXC10) was established based on their strong association with T-cell activity and NSCLC prognosis. The model effectively stratiﬁed patients into high-and low-risk groups with signiﬁcant survival differences, demonstrating strong predictive performance (AUCs of 0.68, 0.72, and 0.69 for 1-, 3-, and 5-year survival in the training cohort) . External validation conﬁrmed its robustness. Anomogram combining risk scores and clinical factors improved survival prediction (AUCs>0 . 6) . High-risk patients responded better to AZD5991-1720, an MCL1 inhibitor, while low-risk patients showed improved responses to IGF1R-3801-1738, an IGF1R inhibitor, suggesting that risk stratiﬁcation may help optimize treatment selection based on tumor-speciﬁc vulnerabilities. qRT-PCR validation conﬁrmed the differential expression of model genes in NSCLC tissues, consistent with TCGA data.  \nConclusion: We identiﬁed a 16-gene T-cell-related prognostic model for NSCLC, which stratiﬁes patients by risk and predicts treatment response, aiding personalized therapy decisions. However, prospective validation is needed to conﬁrm its clinical applicability. Potential limitations such as sample size and generalizability should be considered.  \nKEYWORDS  \nnon-small cell lung cancer, T lymphocyte, prognosis, tumor immune microenvironment, bioinformatics  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nIntroduction  \nNon-small cell lung cancer (NSCLC) remains the le","cbCairXnv1alNXG0","https://ap.wps.com/l/cbCairXnv1alNXG0","pdf",9699986,17,"English","# Background\n# Methods\n# Results\n# Conclusion\n# Keywords","[{\"question\":\"How was the 16-gene T-cell-related prognostic model developed and validated?\",\"answer\":\"The model was constructed from TCGA NSCLC and non-cancer samples using ssGSEA, WGCNA, and differential expression, then fit with LASSO Cox regression. It was externally validated using GEO datasets (GSE50081, GSE31210, GSE30219).\"},{\"question\":\"What does the model do for patient risk stratification and survival prediction?\",\"answer\":\"It classifies patients into high- and low-risk groups with significant survival differences and shows predictive performance measured by AUCs for 1-, 3-, and 5-year survival. A nomogram combining risk scores and clinical factors further improves survival prediction.\"},{\"question\":\"How is the model linked to treatment response and immune biology?\",\"answer\":\"Immune cell infiltration and drug sensitivity were assessed, and differential responses were observed between risk groups for MCL1 and IGF1R inhibitors. qRT-PCR validation confirmed that model genes show differential expression in NSCLC tissues consistent with TCGA data.\"}]","Development and validation of a 16-gene T-cell-related prognostic model in non-small cell lung cancer | PDF",1790160520,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/16952fb61ccf1202ad7373bad0141b6f.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4c1d3f8a3a38ac1876bf5d1eb8d846f4.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90b473bd6e5a9db710990f07745b5254.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/76df6c699ae46c5888157f17d4d94a8a.webp",980,1385]